Table 1 Patient characteristics, by initial neoplasm, of ≥ 1-year adult (≥ 20 years old) survivors in 17 SEER registries, 2000–2017.
Characteristic | NSCLC | Cutaneous Melanoma | RCC | Multiple Myeloma |
|---|---|---|---|---|
n = 222 246 | n = 208 154 | n = 132 199 | n = 49 513 | |
% | % | % | % | |
Age at initial diagnosis, years | ||||
20–39 | 1.2 | 14.3 | 5.4 | 1.8 |
40–49 | 5.7 | 17.2 | 14.0 | 8.7 |
50–59 | 19.7 | 23.7 | 26.5 | 22.8 |
60–69 | 34.3 | 23.2 | 29.6 | 31.8 |
70–79 | 31.9 | 16.9 | 20.1 | 27.5 |
80–83 | 7.3 | 4.8 | 4.4 | 7.5 |
Mean age at initial diagnosis, years | 66.1 | 57.0 | 60.8 | 64.6 |
Median latency for MDS/AML, years | 3.8 | 5.4 | 5.3 | 4.3 |
Median latency for MDS, years | 3.8 | 5.0 | 5.4 | 3.8 |
Median latency for AML, years | 3.6 | 5.6 | 5.3 | 4.9 |
Sex | ||||
Male | 49.8 | 55.7 | 53.7 | 54.7 |
Female | 50.2 | 44.3 | 46.3 | 45.3 |
Race | ||||
White/unknown | 81.0 | 98.7 | 82.7 | 72.5 |
Black | 11.4 | 0.4 | 11.3 | 21.1 |
Other | 7.6 | 0.8 | 6.0 | 6.5 |
Year of first primary malignancy diagnosis | ||||
2000–2005 | 32.4 | 31.4 | 27.2 | 28.4 |
2006–2010 | 29.8 | 29.5 | 30.5 | 28.6 |
2011–2016 | 37.8 | 39.1 | 42.2 | 43.0 |
